StockData
Inmune Bio, Inc. logo

Inmune Bio, Inc. (INMB) stock

INMBNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/30
$0.83−0.07 (-7.50%)

Close on Nov 20, 2026Market cap $22.95MP/E –Yield –

Inmune Bio free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Inmune Bio's free cash flow for the twelve months ending Dec 31, 2025 was -$23.62M. For fiscal 2025 it was -$23.62M.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$23.62M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2025Dec 31, 2025-$3.09M–
Q3 FY2025Sep 30, 2025-$5.63M–

More Inmune Bio figures

See a number that looks wrong?